Dr. Reddy’s Recalls 2.36 Lakh Bottles Of Cholesterol Lowering Tablets From U.S.
Dr. Reddy's Laboratories Ltd. is recalling over 2.36 lakh bottles of Atorvastatin Calcium tablets, used for lowering cholesterol, from the U.S., according to a report by the U.S. health regulator.
Dr. Reddy's Labs Inc. is recalling 2.30 lakh bottles of the calcium tablets on account of “failed impurities/degradation specifications”, the U.S. Food and Drug Administration said in its enforcement report.
Of the total bottles being recalled, 55,126 are of 10 mg strength, 44,894 bottles of 20 mg and 1,30,081 bottles are of 40 mg, it said. The firm is also recalling 6,397 bottles of 80 mg on account of presence of foreign substance: A product complaint was received for a defective tablet with an embedded foreign object observed in a bottle, the report said.
The tablets were manufactured by Dr. Reddy's Labs at its Srikakulam facility, it said. The voluntary recall for the 10 mg, 20 mg and 40 mg tablets from the U.S. and Puerto Rico is a class III recall. For the 80 mg tablets, the recall is of class II, the drug regulator said.
A class II recall is initiated in a “situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,” according to the U.S. FDA. A class III recall is initiated in a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.